galactomannans
Botanicalexperimental
Galactomannans are polysaccharides consisting of a mannose backbone with galactose side groups, more specifically, a (1-4)-linked beta-D-mannopyranose backbone with branchpoints from their 6-positions linked to alpha-D-galactose,. — Wikipedia
Clinical trial activity
8 trials · 8 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
5
Phase 3
2
Phase 4
0
Earliest trial started Sep 30, 2005 (NCT00163722)
Timeline
Indications
Mechanism of action
- Unspecified targetUnclear
unclear
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaGalactomannan ↗
Also known as
- galactomannans
- hydroxypropyl guar galactomannan
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05733780 | Phase 2 | Sep 30, 2023 | Bioxytran Inc. |
| NCT05096052 | Phase 3 | Dec 1, 2021 | ALKE RESEARCH PRIVATE LIMITED, Bioxytran Inc. |
| NCT02868489 | N/A | Dec 1, 2016 | Loma Linda University |
| NCT03374501 | N/A | Nov 30, 2014 | Boston Therapeutics, University of Sydney |
| NCT03375398 | N/A | Mar 31, 2011 | Boston Therapeutics, University of Sydney |
| NCT00840268 | Phase 2 | Feb 1, 2009 | Alcon |
| NCT00760045 | Phase 2 | Aug 1, 2008 | Alcon |
| NCT00163722 | Phase 3 | Sep 30, 2005 | Monash University, National Health and Medical Research Council, Australia |
Showing 8 of 8 trials
Page 1 / 1
Organizations
Research & Development (8)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Alcon | For profit | 2 | 2 | 1 | 2008 |
| Bioxytran Inc. | For profit | 2 | 2 | 2 | 2021 |
| Boston Therapeutics | For profit | 2 | 2 | 1 | 2011 |
| University of Sydney | Academic/Hospital | 2 | 0 | 1 | 2011 |
| ALKE RESEARCH PRIVATE LIMITED | For profit | 1 | 0 | 1 | 2021 |
| Loma Linda University | Academic/Hospital | 1 | 1 | 1 | 2016 |
| Monash University | Academic/Hospital | 1 | 1 | 1 | 2005 |
| National Health and Medical Research Council, Australia | Government | 1 | 0 | 1 | 2005 |
8 organizations
Page 1 / 1